Camlin Fine Q1 FY27 Earnings Call — Analysis (NSE: CAMLINFINE)
Camlin Fine Sciences Q1FY27 revenue rose 28% YoY to ₹519.9 Cr but margins collapsed to ~4% and EBITDA to ~₹9 Cr on raw-material, freight and working-capital financing pressure; management cut FY27 EBITDA margin guidance to 10–11%.
Result quality: poor — Loss widened. Management sentiment: neutral.
The take
Q1FY27 Revenue ₹519.9 Cr ( +28% YoY ) . New guidance — FY27 fy27 consolidated revenue ₹2,200 Cr to ₹2,300 Cr . New story: Vanillin capacity utilization ramp .
Results
Q1FY27 revenue ₹519.9 Cr (+28% YoY, up ~₹100 Cr QoQ); EBITDA ~₹9 Cr; Specialty Ingredients revenue >₹400 Cr with 6.35% EBITDA margin; Aroma negative ₹4–4.5 Cr; Performance Chemicals negative/2.5% EBITDA.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹519.9 Cr | +28% | yoy · Q1FY27 · Revenue INR5,199 million, +28% YoY; ~INR1,000 million above Q4FY26. |
| EBITDA | ₹9 Cr | none · Q1FY27 · Q1FY27 EBITDA as referenced by analyst Avnish Tiwari; management did not dispute. | |
| Specialty Ingredients revenue | ₹400 Cr+ | none · Q1FY27 · Segment revenue >INR4,000 million; straights ₹92.7 Cr, blends >₹300 Cr. | |
| Specialty Ingredients EBITDA margin | 6.35% | none · Q1FY27 · Depressed by raw-material pass-through lag and financing costs. | |
| Aroma EBITDA | ₹-4.5 Cr | none · Q1FY27 · Negative EBITDA on 560 tons vanillin sales. | |
| Performance Chemicals EBITDA margin | 2.5% | none · Q1FY27 · Segment EBITDA negative in Q1FY27 due to diphenol shutdown. | |
| Gross debt | ₹640 Cr | point_in_time · Q1FY27 · As of Q1FY27; ₹670 Cr at 31-Mar-26. Reduction from prepayments on IFC/EXIM loans. |
Guidance
Management lowered FY27 EBITDA guidance to 10–11% margin on ₹2,200–2,300 Cr revenue, implying ₹220–230 Cr EBITDA, and expects Q2FY27 improvement across all three verticals with double-digit consolidated EBITDA margin in Q3FY27.
What management committed to
- [Camlin Fine Sciences] will deliver FY27 consolidated revenue of INR2,200 crore to INR2,300 crore. — INR2,200 crores to INR2,300 crores, FY27
- [Camlin Fine Sciences] will achieve FY27 EBITDA margin of 10% to 11%, implying EBITDA of about INR220 crore to INR230 crore. — 10% to 11%, FY27
- [Camlin Fine Sciences] expects Q2FY27 Aroma segment EBITDA to be positive. — Q2FY27
- [Camlin Fine Sciences] expects Q2FY27 Performance Chemicals segment EBITDA to be positive. — Q2FY27
- [Camlin Fine Sciences] expects Q2FY27 Specialty Ingredients/blends margin to be better than Q1FY27. — Q2FY27
- [Camlin Fine Sciences] expects to return to double-digit consolidated EBITDA margin in Q3FY27. — double-digit, Q3FY27
- [Camlin Fine Sciences] expects FY27 vanillin production/sales of around 3,000 metric tons. — around 3,000 metric tons, FY27
- [Camlin Fine Sciences] expects Q2FY27 vanillin sales of 500–600 metric tons. — 500–600 metric tons, Q2FY27
- [Camlin Fine Sciences] expects Q3FY27 vanillin production and sale of over 1,000 tons. — 1,000 tons plus, Q3FY27
- [Camlin Fine Sciences] expects FY28 EBITDA margin in the region of 12% to 14%. — 12% to 14%, FY28
- [Camlin Fine Sciences] expects blends business to grow at least 20% in FY27, with budget planning for 25–30% growth. — at least 20%; budget 25–30%, FY27
- [Camlin Fine Sciences] will have working-capital credit lines of INR100–150 crore in place within the next 1–1.5 months. — INR100 crores to INR150 crores, Q2FY27
Key themes
Margin reset, raw-material squeeze, vanillin ramp
How the narrative shifted
- Raw material and freight squeeze: Management attributes the Q1 margin collapse primarily to high raw-material prices, availability bottlenecks, and freight rerouting around the Red Sea/Hormuz; they expect pressure to persist while the conflict lasts.
- Vanillin capacity utilization ramp: Vanillin is the key capacity-utilisation story: Q1 was low utilisation on the ethyl vanillin campaign, but 95% customer approvals and a shift to methyl vanillin are positioned to drive positive EBITDA from Q2 and double-digit company margin by Q3.
- Blends growth engine: Blends remain the 'hallmark' business with 20%+ growth and 25–30% budget ambitions; Q1 margin was hurt by lagged pass-through and Brazil fire air-freight costs, but Q2 improvement is assumed.
- Working capital and financing strain: Elongated shipping routes and slower customer collections have pushed working capital needs up, forcing supplier/dealer financing that is eroding gross margin; additional credit lines are being arranged.
- Segment disclosure and restructuring: The company has shifted to million-denominated disclosures and introduced three-segment reporting, saying management now views the business more structurally.
- Diphenol shutdown and strategic alternatives: The diphenol plant is shut because phenol prices make production uneconomical; the company is sourcing Chinese intermediates and will decide by Q3 on alternative use or restart.
Operational commentary
- Segmental disclosure introduced: business split into Specialty Ingredients, Aroma, and Performance Chemicals; Performance Chemicals supplies inter-segment straights/guaiacol at arm's length.
- Specialty Ingredients posted >₹400 Cr revenue (straights ~₹92.7 Cr, blends >₹300 Cr) but EBITDA margin was 6.35%, depressed by raw-material price pass-through lag and supplier/dealer-financing costs.
- Aroma sold 560 tons of vanillin (200 methyl, 350 ethyl) in Q1FY27; 95% customer approval achieved for ethyl vanillin, but low utilisation drove ₹4–4.5 Cr negative EBITDA.
- Performance Chemicals EBITDA was negative/2.5%; diphenol plant shut on uneconomical phenol prices, with hydroquinone sourced from China for next two quarters.
- FY27 vanillin volume scaled down to ~3,000 tons from 3,600–4,000 earlier due to slower ethyl-vanillin ramp and four campaign changeovers costing about four months.
- Brazil fire insurance claim settled at ~20% haircut for ₹40 Cr, recorded as an exceptional item.
- Working-capital cycle elongated by South Africa rerouting and slower customer collections; supplier/dealer financing added ~1–1.5% margin impact.
- CFS Europe liquidation no longer a cash burn; China liquidation underway with ₹10–20 million expected expenditure in Q2FY27.
Analyst Q&A
Q. Given Q1 EBITDA of ~₹9 Cr, how is FY27 EBITDA guidance of ₹250 Cr deliverable?
Nirmal Momaya clarified revised guidance is ₹2,200–2,300 Cr top line with 10–11% EBITDA margin, implying ₹220–230 Cr EBITDA; current cost structure makes it within reach.
Q. Why is Aroma EBITDA negative despite $13–14 realisations and supposedly low fixed costs?
Santosh Parab explained utilisation was only ~25% this quarter, so fixed plant costs were unabsorbed; as utilisation crosses 70–80%, fixed costs get absorbed.
Q. Vanillin FY27 volume was guided at 4,000 tons last call, now 3,000; what changed?
Nirmal Momaya attributed the cut to slower ethyl-vanillin ramp-up to ensure quality, 95% customer approvals, and four campaign changeovers losing about a month each.
Q. Any plans to infuse capital or deleverage beyond internal growth?
Santosh Parab said the company is not at the edge of the hill and is considering options including market price, interest rates and ratings; a final decision will be informed later.
Q. Will Q2 be better and can raw-material cost increases be passed on fully?
Nirmal Momaya said Q2 raw-material pressure remains but some pass-through is possible; maybe half of the blend cost increase can be passed on.
Q. When will additional working-capital credit lines of ₹100–200 Cr close?
Santosh Parab said the consolidated working-capital cycle is ~100 days; the line should be in place in the next 1–1.5 months or at least the funding source will be known.
Research and educational content only. Not investment advice.